摘要
目的:探讨地西他滨治疗骨髓增生异常综合征及难治性急性髓系白血病的临床疗效及安全性。方法:接受地西他滨5d治疗方案(地西他滨20mg.m-2.d-1×5d)的12例患者,应用骨髓细胞学、血常规评价疗效。监测体温、血常规、肝肾功能等观察其不良反应。结果:12例患者中4例获完全缓解,1例部分缓解,1例血液学改善,总有效率50%(6/12)。平均无疾病进展时间为9.67个月。7例患者输血依赖状况改善。4例患者出现Ⅳ度骨髓抑制,发生率为33.3%(4/12)。2例并发感染,感染率16.67%(2/12),其中1例死亡,化疗相关死亡率8.33%(1/12)。其他不良反应可见轻度药物性肝损害等。结论:地西他滨5d治疗方案对骨髓增生异常综合征及难治性急性髓系白血病有效率较高,严重骨髓抑制发生率低,其他不良反应轻微。
Objective：To evaluate the clinical therapeutic effect and safety of decitabine in the treatment for Myelodysplastic Syndromes（MDS） and refractory acute myeloid leukemia（RAML）.Method：12 patients with MDS and refractory AML were treated with decitabine at a dose of 20 mg·m-2·d-1 for 5 days.The bone marrow smear,blood routine test etc were used to evaluate the efficacy of the treatment.Adverse effect of the decitabine treatment was evaluated by monitoring body temperature,liver and kidney function,and blood routine examination.Result：Of the 12 patients,4 patients achieved complete remission,1 patient achieved partial remission,and there was another patient achieved hematological improvement.The overall response rate was 50%.The median time to progression was 9.67 months.The transfusion dependency was improved in 7 patients.The incidence rate of grade Ⅳ bone marrow depression was 33.33%,and the incidence rate of infection was 16.67%（2/14）,One of the two infected patients died,which indicated that the mortality rate of the treatment by decitabine was 8.33%.Mild liver injury was observed.Conclusion：Decitabine can effectively treat MDS and refractory AML.The incidence rate of grade Ⅳ bone marrow depression was low,and other systematic toxicities were mild.
出处
《临床血液学杂志》
CAS
2013年第1期19-22,共4页
Journal of Clinical Hematology
